bis(hydroxyC_{1-6}alkyl)amino, bis(C_{1-6}alkoxyC_{1-6}alkyl)amino, bis(aminoC_{1-6}alkyl)amino, cyano, carboxyl, C_{1-6}alkoxycarbonyl, aryloxycarbonyl, phosphono, C_{1-6}alkylphosphono, diC_{1-6}alkylphosphono, sulfonic acid, and C_{1-6}alkylsulfo); or R_1 and R_2, together with the nitrogen atoms to which they are bound, form a saturated or unsaturated 5- to 7-membered heterocyclic ring containing one nitrogen atom and optionally further containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; and

L is ~~selected from the formula~~:

Claim 2. (**Deleted**).

3. (**Previously Presented**) The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein Z is a hydrogen atom, C_{1-6}alkyl, C_{3-8}cycloalkyl,

hydroxyC_{1-6}alkyl, hydroxyC_{2-6}alkoxyC_{2-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, cyanoC_{1-6}alkyl, pyridylC_{1-6}alkyl, dihydroxyC_{1-6}alkyl, trihydroxyC_{1-6}alkyl, morpholinoC_{1-6}alkyl, (N,N-diC_{1-6}alkylamino)C_{1-6}alkyl, or (N,N-bis(hydroxyC_{1-6}alkyl)amino)C_{1-6}alkyl.

4. **(Previously Presented)** The compound or the pharmaceutically acceptable salt thereof according to claim 3, wherein Z is a hydrogen atom, methyl, ethyl, cyclopropyl, cyclopentyl, 2-hydroxyethyl, 2-(2-hydroxyethoxy)ethyl, 2-methoxyethyl, 2-cyanoethyl, 4-pyridylmethyl, 1-methoxybut-2-yl, 2,3-dihydroxyprop-1-yl, 1,3-dihydroxyprop-2-yl, 1,3-dihydroxy-2-hydroxymethylprop-2-yl, 2-morpholinoethyl, 1-hydroxyprop-2-yl, 1-hydroxy-3-methylbut-2-yl, 2-(N,N-dimethylamino)ethyl, 2-(N,N-bis(2-hydroxyethyl)amino)ethyl, 2,4-dihydroxylbutyl, 2,3,4-trihydroxybutyl, 2,3,4,5-tetrahydroxypentyl, or 2,3,4,5,6-pentahydroxyhexyl.

5. **(Previously Presented)** The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein Y is a halogen atom, cyano, C_{2-7}alkenyl, C_{2-7}alkynyl, C_{1-6}alkoxy, C_{3-6}cycloalkylC_{1-6}alkoxy, C_{3-7}alkynyloxy, or haloC_{1-6}alkoxy.

6. **(Currently Amended)** The compound or the pharmaceutically acceptable salt thereof according to claim 5,

wherein Y is chloro, bromo, cyano, ethynyl, methoxy, trifluoromethoxy, cyclopropylmethoxy, 2-butyn-1-yloxy, or 2-chloroethoxy.

7. **(Previously Presented)** The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein

X_1, X_2, X_3, X_4 and X_5 are each independently selected from a hydrogen atom, a halogen atom, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylthio, and haloC_{1-6}alkylthio; or

X_1 and X_2, X_2 and X_3, X_3 and X_4, and X_4 and X_5, together with the carbon atoms to which they are bound, form a cyclohexane ring, a cyclopentane ring, a benzene ring, a pyridine ring, a pyrimidine ring, a 1,4-dioxane ring, a 1,3-dioxolane ring, a pyrrole ring, an imidazole ring, a thiazole ring, or a furan ring.

8. **(Previously Presented)** The compound or the pharmaceutically acceptable salt thereof according to claim 7, wherein

X_1, X_2, X_3, X_4 and X_5 are each independently selected from a hydrogen atom, fluoro, chloro, bromo, methyl, ethyl, t-butyl, i-propyl, methoxy, i-propoxy, trifluoromethyl, trifluoromethoxy, methylthio, and trifluoromethylthio; or